AJNR. American journal of neuroradiology · 2026
Dynamic Brain [18F] Fluoroestradiol PET Protocol Optimization for Improved Detection of Breast Cancer Brain Metastases.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Elmoujarkach Ezzat, Sharbatdaran Arman, Pontolillo Letizia, Jean Jolie, Agee Matthew, Digregorio Nicholas, Cristofanilli Massimo, Andreopoulou Eleni, Beal Kathryn, Knisely Jonathan P S, Pannullo Susan, Magge Rajiv, Ramakrishna Rohan, Dyke Jonathan, Nehmeh Sadek, Ivanidze Jana
Аннотация
BACKGROUND AND PURPOSE: Brain [18F] fluoroestradiol (FES) PET enables noninvasive assessment of estrogen receptor (ER) expression and may improve the detection of ER-positive (ER+) breast cancer brain metastases (BC-BM), with pilot studies demonstrating clinical utility. Our aim was to leverage our dynamic brain [18F] FES PET acquisition protocol to characterize BC-BM uptake kinetics across different postinjection intervals, with the goal of improving lesion detectability.
MATERIALS AND METHODS: Patients with ER+ primary disease and BC-BM were enrolled prospectively and underwent dynamic [18F] FES PET/CT and contemporaneous standard-of-care contrast-enhanced brain MRI. PET was acquired during 90 minutes using a dynamic protocol (34 frames). Four 15-minute static time windows were reconstructed, including 30-45, 45-60, 60-75, and 75-90 minutes after injection, respectively. MRI was used as the criterion standard for clinical lesion characterization and segmentation, with subsequent [18F] FES PET co-registration. The time window-specific PET MRI lesion matching rate (LMR) and mean standardized uptake value ratio (SUVR, normalized to cerebellar cortex) were calculated.
RESULTS: Eleven patients with a total of 92 MRI-confirmed lesions were included (73 parenchymal, 8 leptomeningeal, 6 calvarial, 4 dural-based, and 1 pituitary stalk). Time window-3 yielded the highest LMR at 68% (63/92 lesions), followed by time window-2 (62%), time window-4 (60%), and time window-1 (57%). The mean SUVR increased across time, with means of 1.83 (standard deviation [SD], 1.46), 2.08 (SD, 1.88), 2.29 (SD, 2.37), and 2.38 (SD, 2.50) for time window-1, -2, -3, and -4, respectively. Despite a higher SUVR at later time points, 8 lesions (6 parenchymal, 1 leptomeningeal, and 1 calvarial) that were visible at 60-75 minutes were undetectable at 75-90 minutes.
CONCLUSIONS: Time window-3 at 60-75 minutes after injection provided optimal LMR for brain [18F] FES PET in ER+ BC and suspected BM. Imaging beyond this interval may not further improve diagnostic yield and may reduce visibility. Limitations of this study include the small cohort size, population heterogeneity regarding prior treatment, and lack of pathologic confirmation. Our findings suggest that 60-75 minutes after injection may represent the optimal acquisition time window and highlight the importance of timing standardization for neuro-oncologic applications of brain [18F] FES PET.
MATERIALS AND METHODS: Patients with ER+ primary disease and BC-BM were enrolled prospectively and underwent dynamic [18F] FES PET/CT and contemporaneous standard-of-care contrast-enhanced brain MRI. PET was acquired during 90 minutes using a dynamic protocol (34 frames). Four 15-minute static time windows were reconstructed, including 30-45, 45-60, 60-75, and 75-90 minutes after injection, respectively. MRI was used as the criterion standard for clinical lesion characterization and segmentation, with subsequent [18F] FES PET co-registration. The time window-specific PET MRI lesion matching rate (LMR) and mean standardized uptake value ratio (SUVR, normalized to cerebellar cortex) were calculated.
RESULTS: Eleven patients with a total of 92 MRI-confirmed lesions were included (73 parenchymal, 8 leptomeningeal, 6 calvarial, 4 dural-based, and 1 pituitary stalk). Time window-3 yielded the highest LMR at 68% (63/92 lesions), followed by time window-2 (62%), time window-4 (60%), and time window-1 (57%). The mean SUVR increased across time, with means of 1.83 (standard deviation [SD], 1.46), 2.08 (SD, 1.88), 2.29 (SD, 2.37), and 2.38 (SD, 2.50) for time window-1, -2, -3, and -4, respectively. Despite a higher SUVR at later time points, 8 lesions (6 parenchymal, 1 leptomeningeal, and 1 calvarial) that were visible at 60-75 minutes were undetectable at 75-90 minutes.
CONCLUSIONS: Time window-3 at 60-75 minutes after injection provided optimal LMR for brain [18F] FES PET in ER+ BC and suspected BM. Imaging beyond this interval may not further improve diagnostic yield and may reduce visibility. Limitations of this study include the small cohort size, population heterogeneity regarding prior treatment, and lack of pathologic confirmation. Our findings suggest that 60-75 minutes after injection may represent the optimal acquisition time window and highlight the importance of timing standardization for neuro-oncologic applications of brain [18F] FES PET.